High-dose cytosine arabinoside in multiple myeloma.
In 14 patients with advanced refractory multiple myeloma, the effect of high-dose cytosine arabinoside (ara-C) administration was evaluated. There was one partial remission among 13 evaluable patients who received 2 g/m2 intravenously over 2 hr every 12 hr, for a total of 2-8 g/m2 per course, repeated every 3-4 weeks. Myelosuppression constituted the dose-limiting toxicity, causing two treatment-related deaths from infection and bleeding. Prior extensive therapy, a low percentage of cells in S phase and low levels of intracellular ara-CTP accumulation in the bone marrow could explain the resistance of myeloma to this treatment.
D000368:Aged; D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism; D001772:Blood Cell Count; D001853:Bone Marrow / Q000378:metabolism / Q000473:pathology; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002452:Cell Count; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007399:Interphase; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate